冷凝集素病市場：現況分析及預測（2023-2030）

由於針對冷凝集素疾病的潛在治療方法的研究和開發不斷增加，預計冷凝集素疾病市場在預測期內將以 18% 的複合年增長率強勁增長。例如，Enjaymo 於 2022 年 2 月獲得 FDA 的美國上市批准，以減少患有中樞神經系統慢性阻塞性疾病的成年人對紅血球輸注的需求。該藥物是 FDA 批准的第一個也是唯一一個用於治療冷凝集素病患者的藥物。它的作用是抑制紅血球的破壞。其他幾個因素，例如臨床試驗數量的增加、研究投資和患者治療結果的改善，也導致了市場的激增。例如，2022年2月，Sanofi進行了1b期臨床試驗，以評估Bioverativ（BIVV020）在冷凝集素疾病患者中的安全性、耐受性和藥物動力學。

依藥物劃分，市場分為皮質類固醇、烷化劑、嘌呤核甘類似物、生物製劑等。由於技術進步和人們對該疾病的認識不斷提高，皮質類固醇細分市場在 2022 年佔據了最高的市場份額。其他因素，例如老年人口的增加，也加強了皮質類固醇在冷凝集素疾病市場中的地位，因為老一代更容易患這種疾病。例如，世界衛生組織（WHO）在2022年10月報告稱，2015年至2050年間，全球60歲及以上人口將幾乎翻倍，從12%增至22%，冷凝集素疾病市場將增加。以穩定的速度推進。因此，皮質類固醇將在2022年佔據很大的市場。

根據給藥途徑，市場分為口服、腸胃外和其他。由於消費便利性、對冷凝集素病等慢性病的認識不斷提高、對微創治療的需求不斷增加以及醫療保健專業人員對此類治療程序的接受程度不斷提高，預計口服藥物細分市場將在預測期內部增長。複合年增長率最高。例如，根據 Frontiers 2021 年 2 月的一篇文章“口服藥物遞送的進展”，最廣泛使用的藥物遞送方法是口服途徑，市場上大約 60% 的小分子藥物都是通過這種方式遞送的。 。因此，預計在預測期內，口腔細分市場將在市場上佔據主導地位。

根據最終用戶，市場分為醫院、專科診所等。醫院類別根據醫院提供的醫療服務的可及性、高素質醫療人員的可用性、先進醫療技術的利用以及世界各地的單位數量的多樣化而按醫院分類。2022 年。例如，根據美國醫院協會2023年的數據，2022年美國共有6,129家醫院，擁有病床診所919,649個，住院病人數為34,011,386人。醫院領域的市場競爭非常激烈，預計這種情況在可預見的未來仍將持續。因此，2022年的市場規模將由醫院產業主導。

為了更了解冷凝集素病產業的市場實施情況，市場已細分為北美（美國、加拿大和北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利和歐洲其他地區），亞太地區（中國、日本、印度、亞太地區其他地區）以及中東和非洲的世界其他地區。預計亞太地區在預測期內將以最高的複合年增長率成長。這是由於市場上存在著大公司、冷凝集素疾病日益流行以及完善的學術和研究機構的存在。例如，2021 年 9 月，Aleph Pharmaceuticals, Inc. 宣佈在日本推出 Ultomiris，用於治療冷凝集素疾病。印度和中國等國家為臨床研究提供了有吸引力的投資機會，預計將積極推動冷凝集素疾病的研發。因此，由於亞太地區人口規模龐大，預計在預測期內將以高複合年增長率成長。

目錄

第一章 市場介紹

• 市場定義
• 主要目標
• 利益相關者
• 限制

第二章 研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章主要市場洞察

第 4 章執行摘要

第五章 新模式對冷凝集素病市場的影響

第六章冷凝集素疾病市場收入，2020-2030

第七章 藥品市場洞察

• 皮質類固醇
• 烷基化劑
• 嘌呤核甘類似物
• 生物製品
• 其他

第 8 章依給藥途徑劃分的市場洞察

• 口服
• 腸外
• 其他

第 9 章 最終用戶的市場洞察

• 醫院
• 專科診所
• 其他

第 10 章 按應用劃分的市場洞察

• 家用
• 非住宅

第十一章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 北美其他地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 亞太其他地區
• 世界其他地區 中東/非洲

第十二章冷凝集素病市場動態

• 市場驅動力
• 市場挑戰
• 影響分析

第十三章冷凝集素疾病市場機會

第十四章冷凝集素病市場趨勢

第十五章需求側與供給面分析

• 需求面分析
• 供給側分析

第十六章價值鏈分析

第17章價格分析

第十八章戰略洞察

第19章 競爭場景

• 競爭格局
• 波特五力分析

第二十章 公司簡介

• Heil
• McNeilus Truck and Manufacturing
• Labrie Group
• Curbtender Sweepers, LLC
• Geesink
• Bridgeport Manufacturing
• FAUN Umwelttechnik GmbH & Co. KG
• Haul-All Equipment Ltd.
• Fratelli Mazzocchia Spa
• Nord Engineering s.p.a

第21章 免責聲明

Cold agglutinin disease (CAD) is a rare autoimmune disorder that can cause the human body to produce antibodies that attack and destroy red blood cells, leading to anemia and other symptoms. It is associated with clonal B-cell lymphoproliferative cells (AIHA). It can be caused by a variety of factors, including genetics, infections, and certain medications. Some common symptoms of CAD include fatigue, weakness, pale skin, shortness of breath, and fever. Symptoms of CAD tend to be exacerbated during cold weather. The cold agglutinin disease market is growing at a tremendous rate owing to a surge in the number of disease cases, increased focus on early detection and prevention, advances in treatment options, and a rise in the geriatric population. For instance, according to the American Society of Hematology in December 2021, the estimated incidence rate of cold agglutinin disease is between 5 and 20 per million individuals and between 0.5 and 1.9 per million individuals per year.

The Cold Agglutinin Disease Market is expected to grow at a strong CAGR of 18% during the forecast period owing to the rising research and developments for finding a potential cure for cold agglutinin disease. For instance, Enjaymo was granted marketing authorization in the U.S. by the FDA in February 2022, with the purpose of reducing the requirement for red blood cell transfusions in adults with chronic obstructive diseases of the central nervous system. This is the first and only FDA-approved treatment for people with cold agglutinin disease. It works by blocking the destruction of red blood cells. Several other factors such as increased number of clinical trials, investment in research, and improved patient outcomes are also leading to the surge in the market. For instance, in February 2022, a Phase 1b clinical study was conducted by Sanofi to evaluate the safety, tolerability, and pharmacokinetics of Bioverativ (BIVV020) in patients with cold agglutin diseases.

Based on drugs, the market is segmented into corticosteroids, alkylating agents, purine nucleoside analogs, biologics, and others. The corticosteroids segment held the highest share in the market in the year 2022 owing to technological progress, and increased awareness of the condition. Other factors such as the rise in the geriatric population are also strengthening grounds for the corticosteroids segment in the cold agglutinin disease market as the older generation is more prone to getting affected by the disease. For instance, the World Health Organization (WHO) reported in October 2022 that between 2015 to 2050, the segment of the world's population over 60 years will nearly double from 12% to 22%, which will propel the cold agglutinin disease market at a steady rate. Hence, the corticosteroids segment held a significant share of the market in the year 2022.

Based on the route of administration, the market is bifurcated into oral, parenteral, and others. The oral segment is expected to grow with the highest CAGR during the forecast period owing to the ease of consumption, growing awareness of chronic conditions like cold agglutinin disease, the increased need for minimally invasive treatments, and the growing acceptance of such treatment procedures by healthcare professionals. For instance, according to Frontiers article, Advances in Oral Drug Delivery in February 2021, the most widely used method of drug administration is through the oral route, with approximately 60% of commercially available small molecule drug products being administered this way. Thus, the oral segment is expected to gain prominence in the market in the forecast period.

Based on end-users, the market is segmented into hospitals, specialty clinics, and others. The hospitals category held the highest share in the market in 2022 attributed to the ease of access to healthcare provided by hospitals, the availability of highly qualified healthcare personnel, the utilization of advanced medical technology, and a diverse number of units all over the globe. For instance, according to the American Hospital Association in 2023, there are in total of 6,129 hospitals in the U.S with 919,649 staffed beds and 34,011,386 hospital admissions in the year 2022. The market for the hospital segment is highly competitive and is projected to remain so in the foreseeable future. Thus, the hospital segment held dominance in the market in the year 2022.

For a better understanding of the market adoption of the cold agglutinin disease industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. This is due to the presence of major players in the market, the increasing incidence of cold agglutinin disorder, and the presence of well-established academic and research institutes. For example, in September 2021, Aleph Pharmaceuticals, Inc., announced that it would launch Ultomiris in Japan for the treatment of cold agglutinin disorder. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for cold agglutinin disease. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.

Some of the major players operating in the market include: Johnson & Johnson Services, Inc., Novartis AG; Bayer AG; Pfizer Inc.; Sanofi; AstraZeneca; Bristol-Myers Squibb Company; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; GSK plc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Waste or Garbage Collection Vehicle Market
• 2.2. Research Methodology of the Waste or Garbage Collection Vehicle Market
• 2.3. Respondent Profile

3 MARKET KEY INSIGHTS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE WASTE OR GARBAGE COLLECTION VEHICLE MARKET

6 WASTE OR GARBAGE COLLECTION VEHICLE MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY LOADER TYPE

• 7.1. Front Loader
• 7.2. Rear Loader
• 7.3. Automated Side Loader
• 7.4. Others

8 MARKET INSIGHTS BY VEHICLE TYPE

• 8.1. Light Duty
• 8.2. Medium Duty
• 8.3. Heavy Duty

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Manual
• 9.2. Semi-Automatic

10 MARKET INSIGHTS BY APPLICATION

• 10.1. Residential
• 10.2. Non-Residential

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. The U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. The U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. India
  • 11.3.3. Japan
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 WASTE OR GARBAGE COLLECTION VEHICLE MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 WASTE OR GARBAGE COLLECTION VEHICLE MARKET OPPORTUNITIES

14 WASTE OR GARBAGE COLLECTION VEHICLE MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 PRICING ANALYSIS

18 STRATEGIC INSIGHTS

19 COMPETITIVE SCENARIO

• 19.1. Competitive Landscape
• 19.2. Porters Fiver Forces Analysis

20 COMPANY PROFILED

• 20.1. Heil
• 20.2. McNeilus Truck and Manufacturing
• 20.3. Labrie Group
• 20.4. Curbtender Sweepers, LLC
• 20.5. Geesink
• 20.6. Bridgeport Manufacturing
• 20.7. FAUN Umwelttechnik GmbH & Co. KG
• 20.8. Haul-All Equipment Ltd.
• 20.9. Fratelli Mazzocchia Spa
• 20.10. Nord Engineering s.p.a

21 DISCLAIMER